<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 /home/lopez/grobid/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">p28, A first in class peptide inhibitor of cop1 binding to p53</title>
			</titleStmt>
			<publicationStmt>
				<publisher>Springer Nature</publisher>
				<availability status="unknown"><p>Copyright Springer Nature</p>
				</availability>
				<date type="published" when="2013-06-04">4 June 2013</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yamada</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Surgery</orgName>
								<orgName type="department" key="dep2">Division of Surgical Oncology</orgName>
								<orgName type="institution">University of Illinois at Chicago College of Medicine</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>IL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Christov</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Surgery</orgName>
								<orgName type="department" key="dep2">Division of Surgical Oncology</orgName>
								<orgName type="institution">University of Illinois at Chicago College of Medicine</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>IL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Shilkaitis</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Surgery</orgName>
								<orgName type="department" key="dep2">Division of Surgical Oncology</orgName>
								<orgName type="institution">University of Illinois at Chicago College of Medicine</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>IL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Bratescu</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Surgery</orgName>
								<orgName type="department" key="dep2">Division of Surgical Oncology</orgName>
								<orgName type="institution">University of Illinois at Chicago College of Medicine</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>IL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Green</surname></persName>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Surgery</orgName>
								<orgName type="department" key="dep2">Division of Surgical Oncology</orgName>
								<orgName type="institution">University of Illinois at Chicago College of Medicine</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>IL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Santini</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Biophysics and Nanoscience Centre</orgName>
								<orgName type="department" key="dep2">Facoltà di Scienze</orgName>
								<orgName type="institution" key="instit1">CNISM</orgName>
								<orgName type="institution" key="instit2">Università della Tuscia</orgName>
								<address>
									<settlement>Viterbo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">R</forename><surname>Bizzarri</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Biophysics and Nanoscience Centre</orgName>
								<orgName type="department" key="dep2">Facoltà di Scienze</orgName>
								<orgName type="institution" key="instit1">CNISM</orgName>
								<orgName type="institution" key="instit2">Università della Tuscia</orgName>
								<address>
									<settlement>Viterbo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Cannistraro</surname></persName>
							<affiliation key="aff1">
								<orgName type="department" key="dep1">Biophysics and Nanoscience Centre</orgName>
								<orgName type="department" key="dep2">Facoltà di Scienze</orgName>
								<orgName type="institution" key="instit1">CNISM</orgName>
								<orgName type="institution" key="instit2">Università della Tuscia</orgName>
								<address>
									<settlement>Viterbo</settlement>
									<country key="IT">Italy</country>
								</address>
							</affiliation>
						</author>
						<author>
							<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">K D</forename><surname>Gupta</surname></persName>
						</author>
						<author role="corresp">
							<persName xmlns="http://www.tei-c.org/ns/1.0"><roleName>Dr</roleName><forename type="first">C</forename><forename type="middle">W</forename><surname>Beattie</surname></persName>
							<email>cbeattie@uic.edu</email>
							<affiliation key="aff0">
								<orgName type="department" key="dep1">Department of Surgery</orgName>
								<orgName type="department" key="dep2">Division of Surgical Oncology</orgName>
								<orgName type="institution">University of Illinois at Chicago College of Medicine</orgName>
								<address>
									<settlement>Chicago</settlement>
									<region>IL</region>
									<country key="US">USA</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">p28, A first in class peptide inhibitor of cop1 binding to p53</title>
					</analytic>
					<monogr>
						<title level="j" type="main">British Journal of Cancer</title>
						<title level="j" type="abbrev">Br J Cancer</title>
						<idno type="ISSN">0007-0920</idno>
						<idno type="eISSN">1532-1827</idno>
						<imprint>
							<publisher>Springer Nature</publisher>
							<biblScope unit="volume">108</biblScope>
							<biblScope unit="issue">12</biblScope>
							<biblScope unit="page" from="2495" to="2504"/>
							<date type="published" when="2013-06-04">4 June 2013</date>
						</imprint>
					</monogr>
					<idno type="DOI">10.1038/bjc.2013.266</idno>
					<idno type="PMID">23736031</idno>
					<idno type="PMCID">PMC3694247</idno>
					<ptr type="open-access" target="https://www.nature.com/articles/bjc2013266.pdf" />
					<note type="submission">Received 26 April 2013; accepted 8 May 2013;</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.6.2-SNAPSHOT" ident="GROBID" when="2020-08-13T22:05+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>p53</term>
					<term>COP1</term>
					<term>cell penetrating peptide</term>
					<term>cell cycle</term>
					<term>ubiquitination</term>
					<term>E3 ligases</term>
				</keywords>
			</textClass>
			<abstract>
				<p>Background: A 28 amino-acid (aa) cell-penetrating peptide (p28) derived from azurin, a redox protein secreted from the opportunistic pathogen Pseudomonas aeruginosa, produces a post-translational increase in p53 in cancer cells by inhibiting its ubiquitination. Methods: In silico computational simulations were used to predict motifs within the p53 DNA-binding domain (DBD) as potential sites for p28 binding. In vitro direct and competitive pull-down studies as well as western blot and RT-PCR analyses were used to validate predictions. Results: The L1 loop (aa 112-124), a region within the S7-S8 loop (aa 214-236) and T140, P142, Q144, W146, R282 and L289 of the p53DBD were identified as potential sites for p28 binding. p28 decreased the level of the E3 ligase COP1 480%, in p53 wt and p53 mut cells with no decrease in COP1 in p53dom/neg or p53null cells. Brief increases in the expression of the E3 ligases, TOPORS, Pirh2 and HDM2 (human double minute 2) in p53 wt and p53 mut cells were in response to sustained increases in p53. Conclusion: These data identify the specific motifs within the DBD of p53 that bind p28 and suggest that p28 inhibition of COP1 binding results in the sustained, post-translational increase in p53 levels and subsequent inhibition of cancer cell growth independent of an HDM2 pathway.</p>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p>The cupredoxin azurin preferentially enters a wide variety of cancer cells, inducing p53-mediated cytostatic and cytotoxic (apoptotic) effects in murine and human cancer cells <ref type="bibr" target="#b48">(Yamada et al, 2002;</ref><ref type="bibr" target="#b33">Punj et al, 2004;</ref><ref type="bibr" target="#b0">Apiyo and Wittung-Stafshede, 2005;</ref>. Molecular modeling and atomic force microscopy studies suggest that azurin binds to the flexible L 1 and S 7 -S 8 loops of the p53 DNA-binding domain (DBD), forming a stable complex through tight protein-protein interactions <ref type="bibr" target="#b9">(De Grandis et al, 2007;</ref><ref type="bibr" target="#b39">Taranta et al, 2008)</ref>. Amino acids (aa) 50-67 (p18) and 50-77 (p28) of azurin represent the protein transport domain <ref type="bibr" target="#b47">(Yamada et al, 2005;</ref><ref type="bibr" target="#b40">Taylor et al, 2009)</ref> and motif <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref> responsible for azurin's antiproliferative activity, respectively. Exposure of p53 wt MCF-7 breast cancer cells to p28 induces a post-translational increase in the level and activity of p53, inhibits the cell cycle at the G 2 -M transition and induces apoptosis, but not in the isogenic p53 dom/neg cell line MDD2 <ref type="bibr" target="#b37">(Shaulian et al, 1992;</ref><ref type="bibr" target="#b49">Yamada et al, 2009)</ref>. Intracellular levels of p53 are tightly regulated by a series of ubiquitin E3 ligases that promote ubiquitination and proteasomal degradation of p53 <ref type="bibr" target="#b30">(Michael and Oren, 2003)</ref>. The most prominent is HDM2 (human double minute 2) <ref type="bibr" target="#b14">(Haupt et al, 1997)</ref>. Current small-molecule HDM2 antagonists MI-219/AT-219, RITA, PXN727, Nutlins (cis-imidazoline analogues) and JNJ-26854165 <ref type="bibr" target="#b8">(Cheok et al, 2011)</ref> bind to HDM2 and inhibit the subsequent ubiquitination and proteolysis of wild-type p53. Unlike these agents, p28 forms a complex <ref type="bibr" target="#b6">(Bizzarri et al, 2011)</ref> within aa 80-276 of the p53DBD that decreases ubiquitination <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref> and proteasomal degradation of p53 via an HDM2-independent pathway <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref>. In addition to HDM2, other E3 ligases, COP1 (constitutively photomorphogenic 1), Pirh2 (p53induced RING-H2 domain protein) and TOPORS (topoisomerase I binding, arginine/serine rich), also reportedly bind to p53 and negatively regulate intracellular levels of p53 <ref type="bibr" target="#b24">(Leng et al, 2003;</ref><ref type="bibr" target="#b10">Dornan et al, 2004a;</ref><ref type="bibr" target="#b12">Dornan et al, 2004b;</ref><ref type="bibr" target="#b34">Rajendra et al, 2004;</ref><ref type="bibr" target="#b11">Dornan et al, 2006;</ref><ref type="bibr" target="#b43">Wang et al, 2011)</ref>. COP1 is reportedly overexpressed in breast, ovarian and hepatocellular carcinomas, and gastric cancer <ref type="bibr" target="#b26">(Li et al, 2012)</ref> predictive of survival in the latter <ref type="bibr" target="#b12">(Dornan et al, 2004b)</ref>, suggesting it contributes to the accelerated degradation of the p53 protein and attenuating the tumour suppressor function of p53 <ref type="bibr" target="#b12">(Dornan et al, 2004b)</ref>. Silencing COP1 inhibits tumour growth and suggests COP1 may be a promising target for systemic therapy <ref type="bibr" target="#b23">(Lee et al, 2010)</ref>.</p><p>In contrast, COP1 also reportedly acts as a developmentally dependent tumour suppressor <ref type="bibr" target="#b31">(Migliorini et al, 2011;</ref><ref type="bibr" target="#b42">Vitari et al, 2011)</ref>, interacting with the oncoprotein c-Jun <ref type="bibr" target="#b3">(Bianchi et al, 2003)</ref> to keep c-Jun at constitutively low levels in vivo and modulate c-Jun/AP-1 transcriptional activity in mice bred to be genetically hypomorphic at the COP1 locus <ref type="bibr" target="#b31">(Migliorini et al, 2011)</ref>. A COP1 deficiency also reportedly leads to c-Jun upregulation in human cancer cells <ref type="bibr" target="#b31">(Migliorini et al, 2011)</ref>, suggesting COP1 is also a tumour suppressor that functions, at least in part, by antagonising c-Jun oncogenic activity in the absence of a genetic interaction between COP1 and p53 <ref type="bibr" target="#b31">(Migliorini et al, 2011)</ref>. Here, we report the underlying mechanism for the post-translational increase in p53 wt,mut levels induced by p28 in breast cancer and melanoma cells. p28 inhibits the binding of COP1 to a specific motif of the p53DBD, leading to an autoreduction in COP1 levels <ref type="bibr" target="#b11">(Dornan et al, 2006)</ref> and an increase in the level of p53 in the absence of any alteration in c-Jun.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>MATERIALS AND METHODS</head><p>Peptide synthesis. p28 (Leu 50 -Asp 77 LSTAADMQGVVTDGMAS GLDKDYLKPDD, 2914 Da) was synthesised by C S Bio, Inc. (Menlo Park, CA, USA) at 495% purity and mass balance.</p><p>Molecular dynamics. Computer simulations were performed essentially as described <ref type="bibr" target="#b9">(De Grandis et al, 2007;</ref>. Configurations for azurin and the DBD of p53 were taken from 1E5Z and 1TUP of PDB files, respectively. The 28 aa of p28 was cut from the crystallographic structure for azurin and used to generate the configuration file subsequently applied to MD simulations at 300 K and P ¼ 1 bar. Complete details for MD are in the Supplementary Materials and Methods. Docking studies. ClusPro <ref type="bibr" target="#b19">(Kozakov et al, 2010)</ref> was used to conduct automated docking as a six-dimensional search within the rotational space between the two molecules. This generated a set of possible configurations for a predicted series of p53DBD-p28 complexes that were ranked based on scoring. The predicted complexes were then subjected to cluster analysis under a pairwise binding site root mean squared deviation criterion. The cluster model with the best score was used to further compare the proteinprotein interface using the ProtorP: Protein-Protein Interface Analysis Server <ref type="bibr" target="#b35">(Reynolds et al, 2009)</ref>.</p><p>Cell proliferation and xenograft tumour assays. Human breast cancer cells MCF-7, p53 wt (ATCC, Manassas, VA, USA), the isogenic MDD2, p53 dom/neg <ref type="bibr" target="#b37">(Shaulian et al, 1992</ref>) (courtesy of Dr Andrei V. Gudkov, Roswell Park Cancer Institute, Buffalo, NY, USA) and MDA-MB-231, p53 mut , as well as normal breast (MCF-10A, p53 wt ) (ATCC) and melanoma cells (UISO-Mel-6, p53 null ; UISO-Mel-23, p53 mut ; UISO-Mel-29, p53 wt ) <ref type="bibr" target="#b17">(Kichina et al, 2003)</ref> were cultured as described <ref type="bibr" target="#b48">(Yamada et al, 2002;</ref><ref type="bibr" target="#b33">Punj et al, 2004;</ref><ref type="bibr" target="#b40">Taylor et al, 2009)</ref>. p28 is a stable peptide that binds to p53 in the cell nucleus <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref> with intracellular concentrations reaching 120 ng ml À 1 (p28) or 0.042 (mmol l À 1 ) 2 h post exposure to 100 mmol l À 1 p28, which eliminated the need for repeated exposure. The effect of p28 on cell growth was determined by direct cell counting <ref type="bibr" target="#b40">(Taylor et al, 2009)</ref>.</p><p>Human melanoma  and breast cancer cells (MCF-7 and MDA-MB-231) were injected s.c. in the right flank of 5-to 6-week-old male and female athymic mice <ref type="bibr" target="#b33">(Punj et al, 2004;</ref><ref type="bibr" target="#b16">Jia et al, 2011;</ref><ref type="bibr" target="#b28">Mehta et al, 2011)</ref>. When tumours reached 3 mm in diameter, animals were randomised into control (20 mice) and treatment (10 mice) groups, and injected i.p. with DTIC (5-(3,3dimethyl-1-triazeno) imidazole-4-carboxamide), 4 mg kg À 1 , 3 Â /week (melanoma); paclitaxel, 12.8 mg kg À 1 i.p., days 10, 14, 21 and 25 (breast cancer); or p28 10 or 20 mg kg À 1 i.p. 3 Â /week for 30 days. Although p28 is rapidly cleared (t ½ 0.06 h; clearance (ml kg À 1 h À 1 ) 2159), it is also rapidly taken up (Vdss (ml kg À 1 ) 297) at pharmacologically active doses <ref type="bibr" target="#b33">(Punj et al, 2004;</ref><ref type="bibr" target="#b16">Jia et al, 2011;</ref><ref type="bibr" target="#b28">Mehta et al, 2011)</ref>. p28 is also stable in murine serum (t 1/2 B60 min) <ref type="bibr" target="#b33">(Punj et al, 2004;</ref><ref type="bibr" target="#b16">Jia et al, 2011;</ref><ref type="bibr" target="#b28">Mehta et al, 2011)</ref> assuring a continuous release of the mature peptide. At necropsy, tumours were dissected, freed of fat and weighed. Statistical comparisons were performed by analysis of variance ANOVA (control vs treatment) (GraphPad InStat ver. 3.0, La Jolla, CA, USA).</p><p>Western blot analysis and RT-PCR. Human breast and melanoma cells were cultured with p28 at 50 mmol l À 1 for 24-72 h, whole-cell lysates prepared and western blot analysis conducted <ref type="bibr" target="#b48">(Yamada et al, 2002;</ref><ref type="bibr" target="#b49">Yamada et al, 2009)</ref>. A list of antibodies used is provided in Supplementary Materials and Methods. Band intensity was determined using UN-SCAN-IT (Silk Scientific Inc., Orem, Utah). Each control and experimental band was normalised by calculating the ratio of a specific protein/actin. Each experimental level was then expressed as the (relative) percentage of control.</p><p>Total RNA was extracted from human breast and melanoma cells exposed to p28, and RT-PCR conducted as previously described <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref>. Primer sets are described under Supplementary Materials. Each control and experimental band was normalised by calculating the ratio of a specific gene/GAPDH. Each experimental level was then expressed as the (relative) percentage of control. The data are representative of at least two independent measures.</p><p>Construction and purification of p53 fragments. Plasmid pGEX5X3 (GE Healthcare, Little Chalfont, United Kingdom) expressing GST fused to fragments of human p53 wt were constructed by PCR <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref>. DNA fragments encoding aa 1-80, 81-300, 81-160, 161-300 and 301-393 of p53 were amplified with specific primer sets (Supplementary Materials and Methods) and GST-fusion proteins purified by Glutathione Sepharose 4B affinity chromatography and HiLoad Superdex 75 gel-filtration column connected to the Ä KTAprime plus FPLC system (GE Healthcare) <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref>.</p><p>GST pull-down assays. p28 binding to fragments of p53 was analysed using a GST pull-down assay <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref>. GST fused to fragments of p53 and GST alone were bound to glutathione-Sepharose 4B beads (GE Healthcare), p28 added and incubated for 2 h. Each sample was loaded on 6% native-PAGE. Membranes were incubated with polyclonal anti-p28 antibody, washed three times with Tris-HCl containing 0.05% Tween 20, secondary rabbit IgG-HRP antibody (Sigma-Aldrich, St Louis, MO, USA). COP1 binding to p53 in the presence or absence of p28 was analysed using competitive pull-down assays <ref type="bibr" target="#b15">(Hosaka et al, 2005)</ref>. GST fused to fragments of p53 were immobilised on beads, followed by incubating with or without p28 (10-100 mole excess). Whole-cell lysates containing COP1 were prepared from MCF-7 cells in PBS containing 0.1% Triton X-100, 10% glycerol and a protease inhibitor cocktail (Sigma-Aldrich). Soluble extracts were incubated with beads, each sample washed with PBS, pelleted and analysed with an anti-COP1 antibody.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>RESULTS</head><p>Docking simulation of p28-p53 complex. ClusPro identified motifs spanning the L 1 loop (aa 112-124), within aa 139-146, a region within the S 7 -S 8 loop (aa 214-236) and R282 and L289 of the p53 DBD <ref type="bibr" target="#b41">(Tu et al, 2008)</ref> that were involved in the binding between p28 and p53 ( <ref type="figure">Figure 1A</ref>). Molecular surface and electrostatic potential plots of the p53DBD were calculated by DeepView ver. 4.0.3 (Swiss Institute of Bioinformatics, Geneva, Switzerland) ( <ref type="figure">Figure 1B)</ref>. A blue, red and white colour gradient represents positive, negative and neutral (including hydrophobic aa) potentials on the molecular surface, respectively. The DNAbinding surface of the p53DBD is highly cationic (blue). In contrast, the p28-binding area is essentially neutral (white), suggesting that electrostatic interaction may not have a role in p28 binding to p53 ( <ref type="figure">Figure 1B)</ref>. The amino-acid composition of the predicted p28-binding sites on p53 was FLHSGTAVTCTYPA LTPQWEGSDCTHRL or 43% hydrophobic, 36% neutral and 21% hydrophilic residues. p28 bound to 10 of 13 aa (77%) in the L 1 loop that were 50% hydrophobic, 40% neutral and 10% hydrophilic residues and 7 of 23 aa (30%), 14% hydrophobic, 43% neutral and 43% hydrophilic, in the S 7 -S 8 loops ( <ref type="figure">Figure 1C</ref>). The four amino acids residing between residues 139 and 147 predicted to bind p28 are 50% hydrophobic and 50% neutral. These residues and the L 1 and S 7 -S 8 loops are not located at or near the DNA-binding surface of p53 (R248 and R273 are direct DNA-binding residues on p53), suggesting p28 does not interfere with the ability of p53 to bind to DNA ( <ref type="figure">Figure 1B)</ref>. The ClusPro best score model also predicted that amino-acid residues LSTAAMQVVGDYLKDD of p28 bind to p53. Fifty per cent of the predicted residues are hydrophobic, again suggesting that hydrophobic rather than electrostatic interaction is essential to the formation of the p28-p53 complex ( <ref type="figure">Figure 1B</ref>). These results agree with computational docking <ref type="bibr" target="#b9">(De Grandis et al, 2007)</ref> studies demonstrating that azurin binds to the L 1 and S 7 -S 8 loops of p53 through interaction of non-polar residues at the interface, creating a short-range hydrophobic interaction. A sequence map of the amino acids predicted to be involved in p28 binding and their relationship to the known binding sites of the E3 ubiquitin ligases that negatively regulate p53 is illustrated in <ref type="figure">Figure 1D</ref>. p28 does not bind to motifs shown to bind either HDM2 or Pirh2.</p><p>GST pull-down assays. p28-binding regions on p53 were mapped using a GST pull-down assay <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref>. GST-p53 1-393 (full length p53), GST-p53 81-300 (p53DBD), GST-p53 81-160 and GST-p53 161-300 pulled down p28, but the N-(GST-p53 1-80 ) and C-terminus of p53 (GST-p53 301-393 ) and GST alone did not ( <ref type="figure">Figure 2A</ref>). These results confirm computerised predictions of regions within the DBD of p53 likely to bind p28 ( <ref type="figure">Figure 1A</ref>-D). We confirmed that binding motifs for p28 and COP1 overlap using competitive pull-down assays of purified GST-p53 and GST alone in the presence of excess p28. p28 induced a significant concentration-dependent reduction in the amount of COP1 <ref type="figure">Figure 1</ref>. Docking model of p28 and p53. (A) The p28-p53 complex structure obtained from the best docking model. Blue: overall ribbon diagram of the p53DBD, green: L 1 and S 7 -S 8 loops. (B) Ribbon diagram of the p53DBD (yellow) superimposed on the electrostatic potential plot. p28 (green) binds to hydrophobic pocket. (C) Relationship of p28 (green) and L 1 (blue) and S 7 -S 8 (yellow) loops of the p53DBD. (D) Map of E3 ligase binding regions superimposed on the full-length sequence of p53. p28-binding residues indicated in red. Binding regions of HDM2, COP1 and Pirh2 indicated in black, green and blue bars, respectively. COP1 binds to p53 in regions separate from HDM2. p28 and COP1 share a binding motif within aa 92-160 of the p53DBD.</p><formula xml:id="formula_0">L 1 loop S 7 -S 8 loop F113 L114 H115 S116 G117 T118 A119 V122 T123 C124 E224 G226 S227 D228 C229 T231 H233 1MEEPQSDPSVEPPLSQETFSDLWKLLPENNVLSPLPSQAMDDLMLSPDDIEQWFTEDPGPDEAPRMPEAA 71PRVAPAPAAPTPAAPAPAPSWPLSSSVPSQKTYQGSYGFRLGFLHSGTAKSVTCTYSPAL 131 NKMFCQLAKTCPVQLWVDSTPPPGTRVRAMAIYKQSQHMTEVVRRCPHHERCSDSDGLAP 191PQHLIRVEGNLRVEYLDDRNTFRHSVVVPYEPPEVGSDCTTIHYNYMCNSSCMGGMNRRP 251 ILTIITLEDSSGNLLGRNSFEVRVCACPGRDRRTEEENLRKKGEPHHELPPGSTKRALSN 311NTSSSPQPKKKPLDGEYFTLQIRGRERFEMFRELNEALELKDAQAGKEPGGSRAHSSHLK 371SKKGQSTSRHKKLMFKTEGPDSD COP1 HDM2 Pirh2 L 1 loop COP1 S 7 -S 8 loop</formula><p>binding to the DBD of p53 ( <ref type="figure">Figure 2B</ref>). Fine mapping of the regions within the p53DBD revealed that p28 inhibited the binding of COP1 to only GST-p53 81-300 and GST-p53 81-160 , clearly demonstrating that p28 inhibits the binding of COP1 to p53 only where their respective binding sites overlap ( <ref type="figure">Figure 2C</ref>).</p><p>Effect of p28 on the growth of human cancer cells. p28 produces a time and dose-related inhibition of p53 wt tumour cell and xenograft growth <ref type="bibr" target="#b49">(Yamada et al, 2009;</ref><ref type="bibr" target="#b16">Jia et al, 2011)</ref>. <ref type="figure" target="#fig_3">Figure 3A</ref> shows that a 72-h exposure to p28 at 50 mmol l À 1 decreased the proliferation of (p53 wt ) Mel-29 and (p53 mut ) Mel-23, where p53 is internally deleted at aa 178-183 <ref type="bibr" target="#b17">(Kichina et al, 2003)</ref>, B25-30% from control. The inhibition was similar to that of 50 mmol l À 1 DTIC. Neither p28 nor DTIC altered the proliferation of p53 null Mel-6 cells. p28 also exhibited significant cytostatic activity on p53 wt MCF-7 breast cancer cells with a similar reduction (B20%) in the number of (p53 mut R280K) MDA-MB-231 cells after 72 h ( <ref type="figure" target="#fig_3">Figure 3B</ref>). These observations, in contrast, p28 did not exhibit an antiproliferative effect on MDD2 (p53 dom/neg ) or normal MCF-10A (p53 wt ) mammary cells confirming previous results <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref>. Paclitaxel at 50 mmol l À 1 inhibited the growth of MCF-7 and MDA-MB-231 breast cancer cells by B90% and MDD2 (p53 dom/neg ) and MCF-10 A (p53 wt ) cells by B50% and 35%, respectively ( <ref type="figure" target="#fig_3">Figure 3B</ref>). p28 also significantly decreased the weight of established p53 wt Mel-29 and p53 mut Mel-23 xenograft tumours in athymic mice ( <ref type="figure" target="#fig_3">Figure 3C</ref>). p28 did not inhibit cell growth of p53 null Mel-6 in vitro ( <ref type="figure" target="#fig_3">Figure 3A</ref>) or in vivo ( <ref type="figure" target="#fig_3">Figure 3C</ref>). p28 also decreased the weight of MCF-7 (p53 wt ) and MDA-MB-213 (p53 mut ) xenograft tumours by B50 and 60% respectively, similar to the effect of a non-toxic dose of paclitaxel <ref type="bibr" target="#b29">(Mi et al, 2002)</ref> ( <ref type="figure" target="#fig_3">Figure 3D</ref>). The significant reduction in growth at 20 mg kg À 1 and lack of effect at 10 mg kg À 1 on MDA-MB-231 cells contrast sharply with the similarity in effect for either dose of p28 on p53 wt MCF-7, Mel-29 or p53 mut Mel-23 cells, suggesting the site of the mutation may be critical to overexpression of p53 ( <ref type="figure" target="#fig_4">Figures 4A and 5A)</ref> and to the overall effect of p28 on the proliferation of p53 mut cancer cells.</p><p>p28 Alters the level of p53 and major downstream targets. The significant decrease in growth following exposure to p28 was associated with a sustained increase in the level of p53 in p53 wt MCF-7 and p53 mut MDA-MB-231 cells ( <ref type="figure" target="#fig_4">Figure 4A</ref>) and p53 wt Mel-29 and p53 mut Mel-23 cells ( <ref type="figure" target="#fig_5">Figure 5A</ref>) with no alteration in the level of transcription of p53 ( <ref type="figure" target="#fig_4">Figures 4B and 5B</ref>), confirming earlier results of an increase in p53 wt MCF-7 cells in response to p28 <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref>. The increase in the level of p53 protein in these lines was also directly associated with an increase in the level of transcription and translation of p21. p28 did not alter either the level or rate of transcription of p53 or p21 in p53 dom/neg MDD2, p53 wt normal MCF-10A or p53 null Mel-6 cells ( <ref type="figure" target="#fig_4">Figures 4A  and B</ref>, and 5A and B). Forkhead box M1 protein (FoxM1), an important regulator of the G 2 -M transition, was significantly reduced in MCF-7, Mel-29 and Mel-23 cells during exposure to p28, increased in p53 dom/neg MDD2 cells at 48-72 h, and remained essentially unchanged in MDA-MB-231, MCF-10A and Mel-6 cells, suggesting that downregulation of FoxM1 also contributed to inhibition of the cell cycle in p53 wt MCF-7, Mel-29 and p53 mut Mel-23 cells. Although this may result from an inability of p53 mut to bind the p53 canonical consensus regions in the FOXM1 promoter, p21 levels were sufficiently elevated to inhibit the proliferation of p53 mut MDA-MB-231 cells, despite the overexpression of FoxM1 ( <ref type="figure" target="#fig_4">Figure 4A</ref>) <ref type="bibr" target="#b1">(Bektas et al, 2008)</ref>. This is not surprising because p53 mutants can often transactivate promoters containing a p21 responsive element <ref type="bibr" target="#b7">(Campomenosi et al, 2001)</ref> and loss of function in mutant p53 breast tumours does not represent a complete absence of activity <ref type="bibr" target="#b45">(Williams et al, 1998)</ref>. STMN1, an inhibitor of microtubule polymerisation <ref type="bibr" target="#b2">(Belmont and Mitchison, 1996)</ref> and critical for cell cycle progression, was not significantly decreased in any cancer cell line tested ( <ref type="figure" target="#fig_4">Figures 4A  and 5A</ref>), suggesting p28 inhibition of the cell cycle at G 2 -M is at G 2 and does not involve inhibition of microtubule formation.</p><p>The p28-induced increase in p53 was associated with a significant decrease in the levels of COP1 in p53 wt and p53 mut breast cancer and melanoma cells ( <ref type="figure" target="#fig_4">Figures 4A and 5A</ref>). Exposure of p53 wt MCF-7 and p53 mut MDA-MB-231 cells to p28 reduced COP1 levels by B70% and 80%, respectively, over 24-72 h without altering the transcription of COP1 ( <ref type="figure" target="#fig_4">Figure 4A</ref>). Exposure of p53 wt Mel-29 to p28 significantly reduced COP1 levels (B75%) at 24 h that gradually increased (B60% of control) at 72 h ( <ref type="figure" target="#fig_5">Figure 5A)</ref>. A similar effect on COP1 levels was observed in p53 mut Mel-23 cells. The lack of effect of p28 on COP1 levels in p53 null Mel-6 and delayed increase in p53 dom/neg MDD2 exposed to p28 suggest that the effects of p28 on COP1 are a function of a cell's p53 status. Moreover, as continued exposure to p28 does not significantly alter COP1 transcription in p53 wt and p53 mut cancer cells, the decrease  <ref type="figure">Figure 2</ref>. p28-binding regions on p53. (A) Purified various fragments of p53 and GST alone were used for a GST pull-down assay. Each sample was analysed by immunoblotting with an anti-p28 antibody. (B) Competitive pull-down assay. Immobilised GST-p53 1-393 and GST alone on glutathione-Sepharose 4B beads were incubated in absence ( À ) or presence of p28 ( þ : 10, þ þ : 100 mole excess), followed by adding MCF-7 lysates containing COP1. Samples were separated by SDS-PAGE and immunoblotted with an anti-COP1 antibody. Lysate: whole-cell lysates of MCF-7 used for the assay showed the stable expression of COP1. Numbers below COP1 bands were relative percentage to the level of COP1 bound to p53 in absence of p28. (C) COP1 binding to various fragments of p53 in absence or presence of p28 was analysed using a similar competitive pull-down assay. Immobilised various fragments of p53 and GST alone were treated with or without p28 (100 mole excess), followed by incubation with MCF-7 lysates containing COP1.</p><p>in the overall level of COP1 likely occurs through autodegradation <ref type="bibr" target="#b11">(Dornan et al, 2006)</ref>.</p><p>p28 Effects on minor E3 ubiquitin ligases. p28 produces a posttranslational increase in p53 through decreased ubiquitination and proteasomal degradation rather than transcriptional activation <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref>. However, exposure to p28 transiently increased the transcription and level of TOPORS (48 h) in p53 wt MCF-7 cells, but did not significantly affect either the transcription or level of TOPORS in p53 mut MDA-MB-231 cells ( <ref type="figure" target="#fig_4">Figure 4A and  B)</ref>. This suggests the upregulation of TOPORS by wild-type p53 was more efficient than with mutated p53. Exposure of p53 wt Mel-29 cells to p28 produced a sustained increase in the level of TOPORS that was not transcription dependent, whereas exposure of p53 mut Mel-23 cells to p28 reduced the level of TOPORS over 48 h, which was not preceded or accompanied by a change in transcription ( <ref type="figure" target="#fig_5">Figure 5 A and B</ref>). The increase in the level and transcription of TOPORS in p53 wt MCF-7 and Mel-29 cells and lack of effect on p53 mut MDA-MB-231 and Mel-23 cells suggest that changes in the level of TOPORS in response to p28 are dependent on p53 status and do not have a major role in the regulation of cell proliferation. p28 also induced a short-term (24 h) increase in the level of Pirh2 in p53 wt MCF-7 and MDA-MB-231 cells without an accompanying increase in transcription, suggesting that the transient increase was in response to the p28-induced increase in p53 ( <ref type="figure" target="#fig_4">Figure 4A and B)</ref>. In contrast, p28 had no significant effect on the expression of the Pirh2 protein or transcription in p53 wt Mel-29 or p53 mut Mel-23 cells ( <ref type="figure" target="#fig_5">Figure 5A and B)</ref>. Collectively, changes in the level of TOPORS and Pirh2 appeared dependent on the cell line treated as well as p53 status and are a minor factor in the regulation of wild-type or mutated p53.</p><p>In contrast, the initial increase (24-48 h) and slow rise (72 h) in the level of the major E3 ligase HDM2 in p53 wt MCF-7 and p53 mut MDA-MB-231 cells, respectively, was accompanied by a parallel increase in transcription. However, neither increase reflected the n =8  sustained increase in p53 in response to p28. Unlike COP1, HDM2 levels were not significantly altered by p28 in p53 wt Mel-29 cells, but increased late in exposure (48-72 h) in p53 mut Mel-23 ( <ref type="figure" target="#fig_5">Figure 5A</ref>).</p><formula xml:id="formula_1">20 mg kg -1 n =8 DTIC n =8 0 * * Mel-23 PBS n =18 10 mg kg -1 n =9 20 mg kg -1 n =8 DTIC n =8 * * Mel-6 PBS n =14 10 mg kg -1 n =6 DTIC n =5</formula><p>p28 Effect on c-Jun. If COP1 acts as a developmentally dependent tumour suppressor <ref type="bibr" target="#b31">(Migliorini et al, 2011;</ref><ref type="bibr" target="#b42">Vitari et al, 2011)</ref>, interacting with the oncoprotein c-Jun <ref type="bibr" target="#b3">(Bianchi et al, 2003)</ref> to keep c-Jun at constitutively low levels in vivo and COP1 deficiency leads to c-Jun upregulation in human cancer cells <ref type="bibr" target="#b31">(Migliorini et al, 2011)</ref> even in the absence of a genetic interaction between COP1 and p53 <ref type="bibr" target="#b31">(Migliorini et al, 2011)</ref>, then exposure to p28 should significantly increase c-Jun levels in p53 wt,mut,null cells. p28 did not significantly alter the level of c-Jun in either p53 wt MCF-7, MDD2 or MCF-10A cells and transiently (48 h) reduced (38%) c-Jun levels in p53 mut MDA-MB-231 breast cancer cells ( <ref type="figure" target="#fig_6">Figure 6A)</ref>. In contrast, c-Jun was significantly decreased over 48-72 h in p53 wt Mel-29 cells, briefly increased (48 h) in p53 mut Mel-23 cells, and only increased slightly over 24 h in p53 null Mel-6 cells ( <ref type="figure" target="#fig_6">Figure 6C</ref>). The decrease in c-Jun in p53 wt Mel-29 cells was accompanied by an increase in transcription (72 h), suggesting the increase was in response to the decrease in the level of the c-Jun protein ( <ref type="figure" target="#fig_6">Figure 6B</ref> and D) rather than the result of a decrease in COP1 following exposure to p28. None of these results suggest that a sustained decrease in COP1 results in an increase in the level and transcription of c-Jun <ref type="bibr" target="#b31">(Migliorini et al, 2011)</ref>. Moreover, the absence of any change in p53, COP1, p21, FOXM1, TORPORS, Pirh2 or HDM2 and the transient increase in c-Jun in p53 null Mel-6 cells in response to p28 suggest that the antiproliferative effects of p28 are mediated via the sustained increase in p53 and p21 independent of any effect on c-Jun <ref type="bibr" target="#b31">(Migliorini et al, 2011)</ref>.</p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>DISCUSSION</head><p>Although most wild-type or mutated p53 tumours must certainly be dysfunctional <ref type="bibr" target="#b46">(Wiman, 2006)</ref>, cancer cells proliferate irrespective of p53 status. This suggests reactivation of p53-induced control of the cell cycle and apoptosis is a plausible therapeutic goal regardless of p53 status. The loss of wild-type p53 function or gain of new oncogenic properties may result, in part, from the numerous missense point mutations within the DBD of p53 clustered into discrete hot spots (R175, G245, R248, R249, R273 and R282) <ref type="bibr" target="#b41">(Tu et al, 2008)</ref>. However, the reported gain-of-function properties reportedly associated with p53 hot spot mutations may not be a universal phenomenon <ref type="bibr" target="#b22">(Lee et al, 2012)</ref>. Amino-acid residues R248 and R273 directly contact DNA while the remainder stabilises the structure of the DNA-binding motif within the DBD <ref type="bibr" target="#b41">(Tu et al, 2008)</ref>. In contrast, the flexible L 1 loop (aa 112-124) within the p53DBD is a mutational cold spot <ref type="bibr" target="#b50">(Zupnick and Prives, 2006)</ref>. Our models predicted that p28 would bind to the L 1 loop, a region of the S 7 -S 8 loop (aa 214-236) and T140, P142, Q144, W146, R282 and L289 of the p53DBD. This prediction was supported by GST pull-down assays <ref type="figure">(Figure 2A</ref>) and atomic force  spectroscopy studies that indicated p28 binds with high affinity to the p53DBD <ref type="bibr" target="#b6">(Bizzarri et al, 2011)</ref>. Once bound, p28 produces an increase in the level of p53 wt,mut ( <ref type="figure" target="#fig_4">Figures 4A and 5A</ref>), which is associated with an inhibition of cell proliferation in vitro and in vivo ( <ref type="figure" target="#fig_3">Figure 3A-D)</ref>. Neither the internal in frame deletion (aa 178-183) <ref type="bibr" target="#b17">(Kichina et al, 2003)</ref> in p53 in Mel-23 cells, which does not include the predicted binding sites for p28, nor the point mutation at R280K in MDA-MB-231 cells that leads to overexpression <ref type="bibr" target="#b32">(Olivier et al, 2002)</ref>  <ref type="figure" target="#fig_4">(Figure 4A</ref>) affects the binding of p28. This suggests that increasing an already elevated level of mutated p53 may also positively impact downstream targets within the cell cycle and apoptotic pathways <ref type="bibr" target="#b27">(Ludwig et al, 1996;</ref><ref type="bibr" target="#b7">Campomenosi et al, 2001)</ref>.</p><p>The FoxM1, a transcription factor for genes regulating the G 2 -M transition, is a major downstream target of p53 <ref type="bibr" target="#b21">(Laoukili et al, 2005)</ref>. Loss of FoxM1 leads to a delay in G 2 <ref type="bibr" target="#b21">(Laoukili et al, 2005)</ref>. p28 reduced the level of FoxM1 in p53 wt MCF-7, p53 wt Mel-29 and p53 mut Mel-23 cells and inhibited cell proliferation, but did not reduce the high basal levels of FoxM1 in triple negative (ER À , PGR À , HER2 À ) p53 mut MDA-MB-231 cells ( <ref type="figure" target="#fig_4">Figure 4A</ref>). The significant inverse correlation between FoxM1 expression and human epidermal growth factor 2 (HER2) <ref type="bibr" target="#b1">(Bektas et al, 2008)</ref> suggests overexpression of FoxM1 may result from this interaction or that the p53 mut R280K in MDA-MB-231 cells may not allow binding to the promoter region of FoxM1. However, p28 did increase the level of p21 in p53 mut MDA-MB-231 cells ( <ref type="figure" target="#fig_4">Figure 4A</ref>), in turn inhibiting the activity of the cyclin-CDK2 complex <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref>. This suggests that inhibition of CDK by p21 provided an alternative pathway for the reduction in growth in the absence of a reduction in FoxM1.</p><p>Intracellular levels of p53 are tightly regulated by a series of ubiquitin E3 ligases that promote ubiquitination and proteasomedependent degradation of p53 <ref type="bibr" target="#b30">(Michael and Oren, 2003)</ref>. HDM2 or MDM2 is the major E3 ligase promoting p53 degradation <ref type="bibr" target="#b14">(Haupt et al, 1997;</ref><ref type="bibr" target="#b20">Kubbutat et al, 1997)</ref>, but TOPORS, Pirh2 and particularly COP1 also bind to and negatively regulate p53 <ref type="bibr" target="#b24">(Leng et al, 2003;</ref><ref type="bibr" target="#b12">Dornan et al, 2004b;</ref><ref type="bibr" target="#b34">Rajendra et al, 2004)</ref>. Although TOPORS is expressed in most normal human tissues <ref type="bibr" target="#b36">(Saleem et al, 2004)</ref>, it is not expressed in colon cancer <ref type="bibr" target="#b34">(Rajendra et al, 2004)</ref> and may not be an E3 ligase critical to p53 function in malignant cells. In contrast, Pirh2 expression is lower in normal compared with tumour cells and appears independent of the type of p53 mutation <ref type="bibr" target="#b13">(Duan et al, 2006)</ref>. The C-terminal domain of Pirh2 <ref type="bibr">(aa 190-261)</ref> binds primarily to the tetramerisation domain (aa 325-355) of p53 <ref type="bibr" target="#b38">(Sheng et al, 2008)</ref> well removed from the binding sites for p28. Exposure to p28 did not reduce Pirh2 levels in either breast cancer or melanoma cells <ref type="figure" target="#fig_4">(Figures 4 and 5)</ref>, producing only short-term increases that were not accompanied by an increase in transcription. This suggests that only extant Pirh2 was recruited to degrade the increasing levels of p53.  p28 significantly increased the level and transcription of HDM2 in p53 wt MCF-7 cells over 24-72 h, while p53 levels remained elevated <ref type="figure" target="#fig_4">(Figure 4</ref>). The increase in HDM2 was minimal and delayed (72 h) in p53 mut MDA-MB-231 cells. p28 had essentially no effect on HDM2 levels or transcription in p53 wt Mel-29, and induced only a delayed increase in HDM2 protein and RNA levels in p53 mut Mel-23 cells in spite of a sustained increase in p53 levels in both cell lines.</p><p>COP1 is overexpressed in breast and ovarian cancers <ref type="bibr" target="#b12">(Dornan et al, 2004b)</ref>, promotes p53 degradation via the proteasome pathway independently of HDM2 or Pirh2 <ref type="bibr" target="#b12">(Dornan et al, 2004b)</ref> and is able to ubiquitinate itself <ref type="bibr" target="#b3">(Bianchi et al, 2003;</ref><ref type="bibr" target="#b11">Dornan et al, 2006)</ref>. We confirm that COP1 binds to aa 92-160 and aa 318-393 of p53 <ref type="bibr" target="#b25">(Li et al, 2009)</ref>. We show that p28 binds to specific motifs within the COP1-binding regions of the p53DBD, blocking COP1 binding and the subsequent ubiquitination and proteasomal degradation of p53. These motifs are distinct ( <ref type="figure">Figure 1D</ref>) from those binding HDM2. The significant reduction in COP1 levels in breast cancer and melanoma cells <ref type="figure" target="#fig_4">(Figures 4 and 5)</ref> is not accompanied by an increase in the transcription of COP1 message, indicating the loss in COP1 is through autodegradation <ref type="bibr" target="#b11">(Dornan et al, 2006)</ref>. The p28-induced reduction in COP1 levels was also not accompanied by a significant or sustained increase in the transcription in c-Jun levels <ref type="bibr" target="#b31">(Migliorini et al, 2011)</ref> that would be expected if a decrease in COP1 levels led to upregulation of c-Jun or altered its ubiquitination. Similarly, overexpression of COP1 does not result in a decrease in steady-state levels of c-Jun nor reduce c-Jun half-life <ref type="bibr" target="#b3">(Bianchi et al, 2003)</ref>.</p><p>The slight, transient increases and decreases in c-Jun levels were also unrelated to alterations in the expression of p53 or in c-Jun transcription ( <ref type="figure" target="#fig_6">Figure 6</ref>) <ref type="bibr" target="#b31">(Migliorini et al, 2011)</ref>, and may result from as yet unknown modulating effects on the steady-state condition of c-Jun in individual cell lines as a result of exposure to p28. The sustained decrease in COP1 levels induced by p28 did not result in a c-Jun-dependent increase in cell proliferation <ref type="figure" target="#fig_3">(Figure 3</ref>) <ref type="bibr" target="#b31">(Migliorini et al, 2011)</ref>, again suggesting that a pharmacologically induced reduction in COP1 levels does not result in a c-Junmediated increase in tumour cell proliferation in either p53 wt or p53 mut cancers <ref type="figure">(Migliorini et al, 2011)</ref>.</p><p>On the basis of our findings, we propose a model for the stabilisation of p53 by p28 that results in a reduction in tumour growth through regulation of cell cycle-related genes. p28 binds to the L 1 loop (aa 112-124) and additional motifs within the COP1-binding regions of the p53DBD <ref type="figure">(Figure 1D</ref>), subsequently inhibiting COP1-mediated p53 proteasomal degradation and stabilising p53. Increased levels of p53 upregulate the downstream molecules p21 <ref type="figure" target="#fig_4">(Figures 4A and 5A</ref>) and p27 <ref type="bibr" target="#b49">(Yamada et al, 2009)</ref> in p53 wt and, at least some, p53 mut cancer cells, downregulating FoxM1, and leading to inhibition of cell cycle at G 2 -M.</p><p>Currently, small molecules designed to inhibit HDM2-mediated ubiquitination are apparently only being tested in patients with p53 wt tumours <ref type="bibr" target="#b18">(Kojima et al, 2010)</ref>. Unlike these small molecules, p28 preferentially enters wide variety of cancer cells <ref type="bibr" target="#b40">(Taylor et al, 2009)</ref> and enhances the cellular level of p53 wt,mut by inhibiting the binding of COP1 independent of the HDM2 pathway. As such, p28 is a prototype molecule that exhibits efficacy in patients with advanced (Stage IV) p53 wt,mut solid tumours <ref type="bibr" target="#b44">(Warso et al, 2013)</ref>.  </p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_3"><head>Figure 3 .</head><label>3</label><figDesc>The effect of p28 on cell and xenograft growth. Human melanoma UISO-Mel-29, -23 and -6 (A) and breast cancer MCF-7, MDD2, MDA-MB-231 and normal MCF-10A cells (B) were exposed to p28, DTIC, paclitaxel or a similar volume of media without peptide for 72 h and cells counted. Values represent the mean ± s.d. of three replicates. Reduction in Mel-23, 29 xenograft growth (C). Reduction of MCF-7, MDA-MB-231 xenograft growth (D). *Po0.05.</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_4"><head>Figure 4 .</head><label>4</label><figDesc>Stabilisation of p53 by E3 ligases on p53 wt,mut breast cancer cells. (A) MCF-7, MDD2, MDA-MB-231, and MCF-10A cells were treated with p28 at 50 mmol l À 1 for 24-72 h. Whole-cell lysates were subjected to western blot analysis. (B) The expression of each gene was determined by RT-PCR. The numbers indicated below each band represent the relative to control (control expressed as 100%).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_5"><head>Figure 5 .</head><label>5</label><figDesc>Stabilisation of p53 by E3 ligases on p53 wt,mut melanoma cells. (A) Mel-29, Mel-23 and Mel-6 cells were treated with p28 at 50 mmol l À 1 for 24-72 h. (B) The expression of each gene was determined by RT-PCR. The numbers indicated below each band represent the relative to control (control expressed as 100%).</figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_6"><head>Figure 6 .</head><label>6</label><figDesc>The effect of p28 on c-Jun. The protein level of c-Jun was determined in MCF-7, MDD2, MDA-MB-231 and MCF-10A cells (A), and Mel-29, Mel-23 and Mel-6 (C) treated with p28 at 50 mmol l À 1 for 24-72 h. The transcription level of c-Jun was determined by RT-PCR in breast cell lines (B) and melanoma cells (D). The numbers indicated below each band represent the relative to control (control expressed as 100%).</figDesc></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">www.bjcancer.com | DOI:10.1038/bjc.2013.266</note>
		</body>
		<back>

			<div type="acknowledgement">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>ACKNOWLEDGEMENTS</head><p>We thank Scott Kennedy for editorial assistance. We thank CDG Therapeutics Inc. for the p28 used in these studies. Financial support was received from the Schenk Chair in Surgical Oncology, the Illinois Health Improvement Association and the NCI-DCT RAID programme. SS, ARB and SC thank the Italian Association for Cancer Research (AIRC No IG 10412) for supporting their research.</p></div>
			</div>

			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>CONFLICT OF INTEREST</head><p>All terms of the research agreement between CDG Therapeutics, Inc., and UIC are managed by UIC in accordance with its conflict of interest management policies. This work is published under the standard license to publish agreement. After 12 months the work will become freely available and the license terms will switch to a Creative Commons Attribution-NonCommercial-Share Alike 3.0 Unported License.</p><p>Supplementary Information accompanies this paper on British Journal of Cancer website (http://www.nature.com/bjc)</p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Unique complex between bacterial azurin and tumor-suppressor protein p53</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Apiyo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pernilla</forename><surname>Wittung-Stafshede</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.bbrc.2005.05.038</idno>
		<idno type="PMID">15913547</idno>
	</analytic>
	<monogr>
		<title level="j">Biochemical and Biophysical Research Communications</title>
		<title level="j" type="abbrev">Biochemical and Biophysical Research Communications</title>
		<idno type="ISSN">0006-291X</idno>
		<imprint>
			<biblScope unit="volume">332</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="965" to="968" />
			<date type="published" when="2005-07" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Tight correlation between expression of the Forkhead transcription factor FOXM1 and HER2 in human breast cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Nuran</forename><surname>Bektas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anette</forename><forename type="middle">Ten</forename><surname>Haaf</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jürgen</forename><surname>Veeck</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Peter</forename><forename type="middle">Johannes</forename><surname>Wild</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Juliane</forename><surname>Lüscher-Firzlaff</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arndt</forename><surname>Hartmann</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ruth</forename><surname>Knüchel</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Edgar</forename><surname>Dahl</surname></persName>
		</author>
		<idno type="DOI">10.1186/1471-2407-8-42</idno>
		<idno type="PMID">18254960</idno>
		<idno type="PMCID">PMC2265720</idno>
		<ptr type="open-access" target="https://bmccancer.biomedcentral.com/track/pdf/10.1186/1471-2407-8-42" />
	</analytic>
	<monogr>
		<title level="j">BMC Cancer</title>
		<title level="j" type="abbrev">BMC Cancer</title>
		<idno type="ISSNe">1471-2407</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page">42</biblScope>
			<date type="published" when="2008-02-06" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Identification of a Protein That Interacts with Tubulin Dimers and Increases the Catastrophe Rate of Microtubules</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lisa</forename><forename type="middle">D</forename><surname>Belmont</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Timothy</forename><forename type="middle">J</forename><surname>Mitchison</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0092-8674(00)81037-5</idno>
		<idno type="PMID">8598048</idno>
		<idno type="PII">S0092-8674(00)81037-5</idno>
		<idno type="ark">ark:/67375/6H6-92KKWSKR-3</idno>
		<idno type="istexId">DF1777A102DEEA71A4C836C808FEAAB7415335B9</idno>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<title level="j" type="abbrev">Cell</title>
		<idno type="ISSN">0092-8674</idno>
		<imprint>
			<biblScope unit="volume">84</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="623" to="631" />
			<date type="published" when="1996-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">Characterization of Human Constitutive Photomorphogenesis Protein 1, a RING Finger Ubiquitin Ligase That Interacts with Jun Transcription Factors and Modulates Their Transcriptional Activity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elisabetta</forename><surname>Bianchi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Simona</forename><surname>Denti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Raffaella</forename><surname>Catena</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Grazisa</forename><surname>Rossetti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Simona</forename><surname>Polo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sona</forename><surname>Gasparian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stella</forename><surname>Putignano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lars</forename><surname>Rogge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ruggero</forename><surname>Pardi</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.m212681200</idno>
		<idno type="PMID">12615916</idno>
		<ptr type="open-access" target="http://www.jbc.org/content/278/22/19682.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Biological Chemistry</title>
		<title level="j" type="abbrev">J. Biol. Chem.</title>
		<idno type="ISSN">0021-9258</idno>
		<idno type="ISSNe">1083-351X</idno>
		<imprint>
			<biblScope unit="volume">278</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="19682" to="19690" />
			<date type="published" when="2003-03-03" />
			<publisher>American Society for Biochemistry &amp; Molecular Biology (ASBMB)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">Atomic Force Spectroscopy in Biological Complex Formation: Strategies and Perspectives</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><forename type="middle">Rita</forename><surname>Bizzarri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Salvatore</forename><surname>Cannistraro</surname></persName>
		</author>
		<idno type="DOI">10.1021/jp902421r</idno>
		<idno type="PMID">19904973</idno>
	</analytic>
	<monogr>
		<title level="j">The Journal of Physical Chemistry B</title>
		<title level="j" type="abbrev">J. Phys. Chem. B</title>
		<idno type="ISSN">1520-6106</idno>
		<idno type="ISSNe">1520-5207</idno>
		<imprint>
			<biblScope unit="volume">113</biblScope>
			<biblScope unit="issue">52</biblScope>
			<biblScope unit="page" from="16449" to="16464" />
			<date type="published" when="2009-12-31" />
			<publisher>American Chemical Society (ACS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">A combined atomic force microscopy imaging and docking study to investigate the complex between p53 DNA binding domain and Azurin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><forename type="middle">Rita</forename><surname>Bizzarri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Silvia</forename><surname>Di Agostino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laura</forename><surname>Andolfi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Salvatore</forename><surname>Cannistraro</surname></persName>
		</author>
		<idno type="DOI">10.1002/jmr.975</idno>
		<idno type="PMID">19642109</idno>
		<idno type="ark">ark:/67375/WNG-KDBTCCZP-W</idno>
		<idno type="istexId">B4BF4E250025E07B9AF081C011C44205E8D2210D</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Molecular Recognition</title>
		<title level="j" type="abbrev">J. Mol. Recognit.</title>
		<idno type="ISSN">0952-3499</idno>
		<idno type="ISSNe">1099-1352</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="506" to="515" />
			<date type="published" when="2009-11" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Interaction of an anticancer peptide fragment of azurin with p53 and its isolated domains studied by atomic force spectroscopy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><forename type="middle">Rita</forename><surname>Bizzarri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Santini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Bucciantini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Di Agostino</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tohru</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><surname>Beattie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Salvatore</forename><surname>Cannistraro</surname></persName>
		</author>
		<idno type="DOI">10.2147/ijn.s26155</idno>
		<idno type="PMID">22162658</idno>
		<idno type="PMCID">PMC3230568</idno>
		<ptr type="open-access" target="https://www.dovepress.com/getfile.php?fileID=11461" />
	</analytic>
	<monogr>
		<title level="j">International Journal of Nanomedicine</title>
		<title level="j" type="abbrev">IJN</title>
		<idno type="ISSNe">1178-2013</idno>
		<imprint>
			<biblScope unit="volume">6</biblScope>
			<biblScope unit="page">3011</biblScope>
			<date type="published" when="2011-11" />
			<publisher>Dove Medical Press Ltd.</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">p53 mutants can often transactivate promoters containing a p21 but not Bax or PIG3 responsive elements</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paola</forename><surname>Campomenosi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Paola</forename><surname>Monti</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><surname>Aprile</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Angelo</forename><surname>Abbondandolo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thierry</forename><surname>Frebourg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Barry</forename><surname>Gold</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tim</forename><surname>Crook</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alberto</forename><surname>Inga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">A</forename><surname>Resnick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Richard</forename><surname>Iggo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gilberto</forename><surname>Fronza</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.onc.1204468</idno>
		<idno type="PMID">11429705</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/1204468.pdf" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<title level="j" type="abbrev">Oncogene</title>
		<idno type="ISSN">0950-9232</idno>
		<idno type="ISSNe">1476-5594</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">27</biblScope>
			<biblScope unit="page" from="3573" to="3579" />
			<date type="published" when="2001-06" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<analytic>
		<title level="a" type="main">Translating p53 into the clinic</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chit</forename><forename type="middle">Fang</forename><surname>Cheok</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chandra</forename><forename type="middle">S</forename><surname>Verma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">José</forename><surname>Baselga</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">P</forename><surname>Lane</surname></persName>
		</author>
		<idno type="DOI">10.1038/nrclinonc.2010.174</idno>
		<idno type="PMID">20975744</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Reviews Clinical Oncology</title>
		<title level="j" type="abbrev">Nat Rev Clin Oncol</title>
		<idno type="ISSN">1759-4774</idno>
		<idno type="ISSNe">1759-4782</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="25" to="37" />
			<date type="published" when="2010-10-26" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Docking study and free energy simulation of the complex between p53 DNA-binding domain and azurin</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Valentina</forename><surname>De Grandis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><forename type="middle">Rita</forename><surname>Bizzarri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Salvatore</forename><surname>Cannistraro</surname></persName>
		</author>
		<idno type="DOI">10.1002/jmr.840</idno>
		<idno type="PMID">17703463</idno>
		<idno type="ark">ark:/67375/WNG-S6HK10XH-G</idno>
		<idno type="istexId">B4339E7667EDB1B12FE00C73AD82A8F879FD7F82</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Molecular Recognition</title>
		<title level="j" type="abbrev">J. Mol. Recognit.</title>
		<idno type="ISSN">0952-3499</idno>
		<idno type="ISSNe">1099-1352</idno>
		<imprint>
			<biblScope unit="volume">20</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="215" to="226" />
			<date type="published" when="2007" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">COP1, the Negative Regulator of p53, Is Overexpressed in Breast and Ovarian Adenocarcinomas</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Dornan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sheila</forename><surname>Bheddah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kim</forename><surname>Newton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">William</forename><surname>Ince</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gretchen</forename><forename type="middle">D</forename><surname>Frantz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrick</forename><surname>Dowd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hartmut</forename><surname>Koeppen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vishva</forename><forename type="middle">M</forename><surname>Dixit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dorothy</forename><forename type="middle">M</forename><surname>French</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.can-04-2601</idno>
		<idno type="PMID">15492238</idno>
		<ptr type="open-access" target="http://cancerres.aacrjournals.org/content/64/20/7226.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<title level="j" type="abbrev">Cancer Res</title>
		<idno type="ISSN">0008-5472</idno>
		<idno type="ISSNe">1538-7445</idno>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="7226" to="7230" />
			<date type="published" when="2004-10-15" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">ATM Engages Autodegradation of the E3 Ubiquitin Ligase COP1 After DNA Damage</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Dornan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><surname>Shimizu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Mah</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Dudhela</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Eby</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>O'rourke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Seshagiri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">M</forename><surname>Dixit</surname></persName>
		</author>
		<idno type="DOI">10.1126/science.1127335</idno>
		<idno type="PMID">16931761</idno>
	</analytic>
	<monogr>
		<title level="j">Science</title>
		<title level="j" type="abbrev">Science</title>
		<idno type="ISSN">0036-8075</idno>
		<idno type="ISSNe">1095-9203</idno>
		<imprint>
			<biblScope unit="volume">313</biblScope>
			<biblScope unit="issue">5790</biblScope>
			<biblScope unit="page" from="1122" to="1126" />
			<date type="published" when="2006-08-25" />
			<publisher>American Association for the Advancement of Science (AAAS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">The ubiquitin ligase COP1 is a critical negative regulator of p53</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Dornan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ingrid</forename><surname>Wertz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Harumi</forename><surname>Shimizu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Arnott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gretchen</forename><forename type="middle">D</forename><surname>Frantz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patrick</forename><surname>Dowd</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karen</forename><surname>O' Rourke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hartmut</forename><surname>Koeppen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vishva</forename><forename type="middle">M</forename><surname>Dixit</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature02514</idno>
		<idno type="PMID">15103385</idno>
		<idno type="ark">ark:/67375/GT4-F6LB29CV-C</idno>
		<idno type="istexId">EDB3A6DCE6F18F994C20E64FFD5D563F8E3C029F</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<title level="j" type="abbrev">Nature</title>
		<idno type="ISSN">0028-0836</idno>
		<idno type="ISSNe">1476-4679</idno>
		<imprint>
			<biblScope unit="volume">429</biblScope>
			<biblScope unit="issue">6987</biblScope>
			<biblScope unit="page" from="86" to="92" />
			<date type="published" when="2004-04-21" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">Differential response between the p53 ubiquitin–protein ligases Pirh2 and MdM2 following DNA damage in human cancer cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wenrui</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Li</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xin</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yang</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gregory</forename><forename type="middle">A</forename><surname>Otterson</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Miguel</forename><forename type="middle">A</forename><surname>Villalona-Calero</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.yexcr.2006.07.005</idno>
		<idno type="PMID">16934800</idno>
	</analytic>
	<monogr>
		<title level="j">Experimental Cell Research</title>
		<title level="j" type="abbrev">Experimental Cell Research</title>
		<idno type="ISSN">0014-4827</idno>
		<imprint>
			<biblScope unit="volume">312</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="3370" to="3378" />
			<date type="published" when="2006-10" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Mdm2 promotes the rapid degradation of p53</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ygal</forename><surname>Haupt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ruth</forename><surname>Maya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anat</forename><surname>Kazaz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Moshe</forename><surname>Oren</surname></persName>
		</author>
		<idno type="DOI">10.1038/387296a0</idno>
		<idno type="PMID">9153395</idno>
		<idno type="ark">ark:/67375/GT4-0B90Z2X0-K</idno>
		<idno type="istexId">BB6B6222E4C9D38EC0E4934CE7B53B7F508DB1EB</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<title level="j" type="abbrev">Nature</title>
		<idno type="ISSN">0028-0836</idno>
		<idno type="ISSNe">1476-4687</idno>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="issue">6630</biblScope>
			<biblScope unit="page" from="296" to="299" />
			<date type="published" when="1997-05" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">Interaction between secretogranin III and carboxypeptidase E facilitates prohormone sorting within secretory granules</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Hosaka</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Watanabe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y</forename><surname>Sakai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Kato</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Takeuchi</surname></persName>
		</author>
		<idno type="DOI">10.1242/jcs.02608</idno>
		<idno type="PMID">16219686</idno>
		<ptr type="open-access" target="http://jcs.biologists.org/content/118/20/4785.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Cell Science</title>
		<title level="j" type="abbrev">Journal of Cell Science</title>
		<idno type="ISSN">0021-9533</idno>
		<idno type="ISSNe">1477-9137</idno>
		<imprint>
			<biblScope unit="volume">118</biblScope>
			<biblScope unit="issue">20</biblScope>
			<biblScope unit="page" from="4785" to="4795" />
			<date type="published" when="2005-10-15" />
			<publisher>The Company of Biologists</publisher>
		</imprint>
	</monogr>
	<note>Part 20</note>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">Preclinical pharmacokinetics, metabolism, and toxicity of azurin-p28 (NSC745104) a peptide inhibitor of p53 ubiquitination</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lee</forename><surname>Jia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gregory</forename><forename type="middle">S</forename><surname>Gorman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lori</forename><forename type="middle">U</forename><surname>Coward</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Patricia</forename><forename type="middle">E</forename><surname>Noker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Mccormick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Thomas</forename><forename type="middle">L</forename><surname>Horn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">Brooks</forename><surname>Harder</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Miguel</forename><surname>Muzzio</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bellur</forename><surname>Prabhakar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Balaji</forename><surname>Ganesh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tapas</forename><forename type="middle">K</forename><surname>Das Gupta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Craig</forename><forename type="middle">W</forename><surname>Beattie</surname></persName>
		</author>
		<idno type="DOI">10.1007/s00280-010-1518-3</idno>
		<idno type="PMID">21085965</idno>
		<idno type="ark">ark:/67375/VQC-JDZ4TKTF-7</idno>
		<idno type="istexId">3896CFD65721220F5117E9D2C75B1B4F7F294D9D</idno>
	</analytic>
	<monogr>
		<title level="j">Cancer Chemotherapy and Pharmacology</title>
		<title level="j" type="abbrev">Cancer Chemother Pharmacol</title>
		<idno type="ISSN">0344-5704</idno>
		<idno type="ISSNe">1432-0843</idno>
		<imprint>
			<biblScope unit="volume">68</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="513" to="524" />
			<date type="published" when="2010-11-18" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Melanoma cells can tolerate high levels of transcriptionally active endogenous p53 but are sensitive to retrovirus-transduced p53</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Julia</forename><forename type="middle">V</forename><surname>Kichina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sikha</forename><surname>Rauth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tapas</forename><forename type="middle">K</forename><surname>Das Gupta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrei</forename><forename type="middle">V</forename><surname>Gudkov</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.onc.1206741</idno>
		<idno type="PMID">12894234</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/1206741.pdf" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<title level="j" type="abbrev">Oncogene</title>
		<idno type="ISSN">0950-9232</idno>
		<idno type="ISSNe">1476-5594</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">31</biblScope>
			<biblScope unit="page" from="4911" to="4917" />
			<date type="published" when="2003-07" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">The Novel Tryptamine Derivative JNJ-26854165 Induces Wild-Type p53- and E2F1-Mediated Apoptosis in Acute Myeloid and Lymphoid Leukemias</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kojima</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">K</forename><surname>Burks</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Arts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Andreeff</surname></persName>
		</author>
		<idno type="DOI">10.1158/1535-7163.mct-10-0337</idno>
		<idno type="PMID">20736344</idno>
		<idno type="PMCID">PMC2949269</idno>
		<ptr type="open-access" target="http://mct.aacrjournals.org/content/9/9/2545.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Molecular Cancer Therapeutics</title>
		<title level="j" type="abbrev">Molecular Cancer Therapeutics</title>
		<idno type="ISSN">1535-7163</idno>
		<idno type="ISSNe">1538-8514</idno>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="2545" to="2557" />
			<date type="published" when="2010-08-24" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Achieving reliability and high accuracy in automated protein docking: Cluspro, PIPER, SDU, and stability analysis in CAPRI rounds 13-19</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dima</forename><surname>Kozakov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><forename type="middle">R</forename><surname>Hall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dmitri</forename><surname>Beglov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ryan</forename><surname>Brenke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">R</forename><surname>Comeau</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yang</forename><surname>Shen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Keyong</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jiefu</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pirooz</forename><surname>Vakili</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ioannis</forename><forename type="middle">Ch. </forename><surname>Paschalidis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sandor</forename><surname>Vajda</surname></persName>
		</author>
		<idno type="DOI">10.1002/prot.22835</idno>
		<idno type="PMID">20818657</idno>
		<idno type="PMCID">PMC3027207</idno>
		<idno type="ark">ark:/67375/WNG-L33NF3BC-X</idno>
		<idno type="istexId">350DA6204FA8E102E8FB4EA5A267853B9C8D88AC</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc3027207?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Proteins: Structure, Function, and Bioinformatics</title>
		<title level="j" type="abbrev">Proteins</title>
		<idno type="ISSN">0887-3585</idno>
		<imprint>
			<biblScope unit="volume">78</biblScope>
			<biblScope unit="issue">15</biblScope>
			<biblScope unit="page" from="3124" to="3130" />
			<date type="published" when="2010-09-03" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Regulation of p53 stability by Mdm2</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Michael</forename><forename type="middle">H G</forename><surname>Kubbutat</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><forename type="middle">N</forename><surname>Jones</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karen</forename><forename type="middle">H</forename><surname>Vousden</surname></persName>
		</author>
		<idno type="DOI">10.1038/387299a0</idno>
		<idno type="PMID">9153396</idno>
		<idno type="ark">ark:/67375/GT4-PST8N9FH-G</idno>
		<idno type="istexId">C9BF51C249FFFD9C6521F633028613A2F415BD9D</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<title level="j" type="abbrev">Nature</title>
		<idno type="ISSN">0028-0836</idno>
		<idno type="ISSNe">1476-4687</idno>
		<imprint>
			<biblScope unit="volume">387</biblScope>
			<biblScope unit="issue">6630</biblScope>
			<biblScope unit="page" from="299" to="303" />
			<date type="published" when="1997-05" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">FoxM1 is required for execution of the mitotic programme and chromosome stability</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jamila</forename><surname>Laoukili</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Matthijs</forename><forename type="middle">R H</forename><surname>Kooistra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexandra</forename><surname>Brás</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jos</forename><surname>Kauw</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ron</forename><forename type="middle">M</forename><surname>Kerkhoven</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ashby</forename><surname>Morrison</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hans</forename><surname>Clevers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">René</forename><forename type="middle">H</forename><surname>Medema</surname></persName>
		</author>
		<idno type="DOI">10.1038/ncb1217</idno>
		<idno type="PMID">15654331</idno>
		<idno type="ark">ark:/67375/GT4-8QST3FFJ-C</idno>
		<idno type="istexId">2E26BF2C173CBB688F44D27258F644CDE1EB56F1</idno>
	</analytic>
	<monogr>
		<title level="j">Nature Cell Biology</title>
		<title level="j" type="abbrev">Nat Cell Biol</title>
		<idno type="ISSN">1465-7392</idno>
		<idno type="ISSNe">1476-4679</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="126" to="136" />
			<date type="published" when="2005-01-16" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Cell-type, Dose, and Mutation-type Specificity Dictate Mutant p53 Functions In Vivo</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ming</forename><forename type="middle">Kei</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei</forename><forename type="middle">Wei</forename><surname>Teoh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Beng</forename><forename type="middle">Hooi</forename><surname>Phang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei</forename><forename type="middle">Min</forename><surname>Tong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhao</forename><forename type="middle">Qi</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kanaga</forename><surname>Sabapathy</surname></persName>
		</author>
		<idno type="DOI">10.1016/j.ccr.2012.10.022</idno>
		<idno type="PMID">23238012</idno>
		<ptr type="open-access" target="http://www.cell.com/article/S1535610812004461/pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Cell</title>
		<title level="j" type="abbrev">Cancer Cell</title>
		<idno type="ISSN">1535-6108</idno>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="751" to="764" />
			<date type="published" when="2012-12" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Definition of Ubiquitination Modulator COP1 as a Novel Therapeutic Target in Human Hepatocellular Carcinoma</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Y-H</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">B</forename><surname>Andersen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H-T</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">D</forename><surname>Judge</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Seo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Ishikawa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">U</forename><surname>Marquardt</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Kitade</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">E</forename><surname>Durkin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Raggi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">H</forename><forename type="middle">G</forename><surname>Woo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><forename type="middle">A</forename><surname>Conner</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Avital</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">I</forename><surname>Maclachlan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><forename type="middle">M</forename><surname>Factor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">S</forename><surname>Thorgeirsson</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.can-10-0749</idno>
		<idno type="PMID">20959491</idno>
		<idno type="PMCID">PMC2970744</idno>
		<ptr type="open-access" target="http://cancerres.aacrjournals.org/content/70/21/8264.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<title level="j" type="abbrev">Cancer Research</title>
		<idno type="ISSN">0008-5472</idno>
		<idno type="ISSNe">1538-7445</idno>
		<imprint>
			<biblScope unit="volume">70</biblScope>
			<biblScope unit="issue">21</biblScope>
			<biblScope unit="page" from="8264" to="8269" />
			<date type="published" when="2010-10-19" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Pirh2, a p53-Induced Ubiquitin-Protein Ligase, Promotes p53 Degradation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Roger</forename><forename type="middle">P</forename><surname>Leng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yunping</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Weili</forename><surname>Ma</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Hong</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Benedicte</forename><surname>Lemmers</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stephen</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">M</forename><surname>Parant</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guillermina</forename><surname>Lozano</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Razqallah</forename><surname>Hakem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Samuel</forename><surname>Benchimol</surname></persName>
		</author>
		<idno type="DOI">10.1016/s0092-8674(03)00193-4</idno>
		<idno type="PMID">12654245</idno>
	</analytic>
	<monogr>
		<title level="j">Cell</title>
		<title level="j" type="abbrev">Cell</title>
		<idno type="ISSN">0092-8674</idno>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="779" to="791" />
			<date type="published" when="2003-03" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">MTA1 Coregulator Regulates p53 Stability and Function</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Da-Qiang</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sirigiri</forename><surname>Divijendra Natha Reddy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Suresh</forename><forename type="middle">B</forename><surname>Pakala</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xifeng</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yanping</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Suresh</forename><forename type="middle">K</forename><surname>Rayala</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rakesh</forename><surname>Kumar</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.m109.056499</idno>
		<idno type="PMID">19837670</idno>
		<idno type="PMCID">PMC2787316</idno>
		<ptr type="open-access" target="http://www.jbc.org/content/284/50/34545.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Biological Chemistry</title>
		<title level="j" type="abbrev">J. Biol. Chem.</title>
		<idno type="ISSN">0021-9258</idno>
		<idno type="ISSNe">1083-351X</idno>
		<imprint>
			<biblScope unit="volume">284</biblScope>
			<biblScope unit="issue">50</biblScope>
			<biblScope unit="page" from="34545" to="34552" />
			<date type="published" when="2009-10-16" />
			<publisher>American Society for Biochemistry &amp; Molecular Biology (ASBMB)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">High Level of COP1 Expression is Associated with Poor Prognosis in Primary Gastric Cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yuan-Fang</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dan-Dan</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bai-Wei</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chun-Yu</forename><surname>Huang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yong-Ming</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yan</forename><surname>Zheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rajiv</forename><forename type="middle">Prasad</forename><surname>Keshari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jian-Chuan</forename><surname>Xia</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zhi-Wei</forename><surname>Zhou</surname></persName>
		</author>
		<idno type="DOI">10.7150/ijbs.4778</idno>
		<idno type="PMID">23091414</idno>
		<idno type="PMCID">PMC3477686</idno>
		<ptr type="open-access" target="http://www.ijbs.com/v08p1168.pdf" />
	</analytic>
	<monogr>
		<title level="j">International Journal of Biological Sciences</title>
		<title level="j" type="abbrev">Int. J. Biol. Sci.</title>
		<idno type="ISSN">1449-2288</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1168" to="1177" />
			<date type="published" when="2012" />
			<publisher>Ivyspring International Publisher</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Differential activation of target cellular promoters by p53 mutants with impaired apoptotic function.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">L</forename><surname>Ludwig</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Bates</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">H</forename><surname>Vousden</surname></persName>
		</author>
		<idno type="DOI">10.1128/mcb.16.9.4952</idno>
		<idno type="PMID">8756654</idno>
		<idno type="PMCID">PMC231497</idno>
		<ptr type="open-access" target="http://mcb.asm.org/content/16/9/4952.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Molecular and Cellular Biology</title>
		<title level="j" type="abbrev">Mol. Cell. Biol.</title>
		<idno type="ISSN">0270-7306</idno>
		<idno type="ISSNe">1098-5549</idno>
		<imprint>
			<biblScope unit="volume">16</biblScope>
			<biblScope unit="issue">9</biblScope>
			<biblScope unit="page" from="4952" to="4960" />
			<date type="published" when="1996-09" />
			<publisher>American Society for Microbiology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">A cell penetrating peptide derived from azurin inhibits angiogenesis and tumor growth by inhibiting phosphorylation of VEGFR-2, FAK and Akt</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rajeshwari</forename><forename type="middle">R</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tohru</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Brad</forename><forename type="middle">N</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Konstantin</forename><surname>Christov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Marissa</forename><forename type="middle">L</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dibyen</forename><surname>Majumdar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Fatima</forename><surname>Lekmine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chinnaswamy</forename><surname>Tiruppathi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anne</forename><surname>Shilkaitis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laura</forename><surname>Bratescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Albert</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Craig</forename><forename type="middle">W</forename><surname>Beattie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tapas</forename><forename type="middle">K</forename><surname>Das Gupta</surname></persName>
		</author>
		<idno type="DOI">10.1007/s10456-011-9220-6</idno>
		<idno type="PMID">21667138</idno>
		<idno type="ark">ark:/67375/VQC-R31C1B1P-G</idno>
		<idno type="istexId">02D2AB133A0D80B73E966C95E88DFC0F37DACB0B</idno>
	</analytic>
	<monogr>
		<title level="j">Angiogenesis</title>
		<title level="j" type="abbrev">Angiogenesis</title>
		<idno type="ISSN">0969-6970</idno>
		<idno type="ISSNe">1573-7209</idno>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="355" to="369" />
			<date type="published" when="2011-06-11" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Evaluation of the Potential Cancer Chemotherapeutic Efficacy of Natural Product Isolates Employing in Vivo Hollow Fiber Tests1</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Qiuwen</forename><surname>Mi</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Daniel</forename><surname>Lantvit</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eulenia</forename><surname>Reyes-Lim</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Heebyung</forename><surname>Chai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Weimin</forename><surname>Zhao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ik-Soo</forename><surname>Lee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sergio</forename><surname>Peraza-Sánchez</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Olipa</forename><surname>Ngassapa</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leonardus</forename><forename type="middle">B S</forename><surname>Kardono</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Soedarsono</forename><surname>Riswan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Melinda</forename><forename type="middle">G</forename><surname>Hollingshead</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Joseph</forename><forename type="middle">G</forename><surname>Mayo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Norman</forename><forename type="middle">R</forename><surname>Farnsworth</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Geoffrey</forename><forename type="middle">A</forename><surname>Cordell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">Douglas</forename><surname>Kinghorn</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">John</forename><forename type="middle">M</forename><surname>Pezzuto</surname></persName>
		</author>
		<idno type="DOI">10.1021/np010322w</idno>
		<idno type="PMID">12088425</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Natural Products</title>
		<title level="j" type="abbrev">J. Nat. Prod.</title>
		<idno type="ISSN">0163-3864</idno>
		<idno type="ISSNe">1520-6025</idno>
		<imprint>
			<biblScope unit="volume">65</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="842" to="850" />
			<date type="published" when="2002-06" />
			<publisher>American Chemical Society (ACS)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">The p53–Mdm2 module and the ubiquitin system</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dan</forename><surname>Michael</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Moshe</forename><surname>Oren</surname></persName>
		</author>
		<idno type="DOI">10.1016/s1044-579x(02)00099-8</idno>
		<idno type="PMID">12507556</idno>
	</analytic>
	<monogr>
		<title level="j">Seminars in Cancer Biology</title>
		<title level="j" type="abbrev">Seminars in Cancer Biology</title>
		<idno type="ISSN">1044-579X</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="49" to="58" />
			<date type="published" when="2003-02" />
			<publisher>Elsevier BV</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b31">
	<analytic>
		<title level="a" type="main">Cop1 constitutively regulates c-Jun protein stability and functions as a tumor suppressor in mice</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Domenico</forename><surname>Migliorini</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sven</forename><surname>Bogaerts</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dieter</forename><surname>Defever</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rajesh</forename><surname>Vyas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Geertrui</forename><surname>Denecker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Enrico</forename><surname>Radaelli</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Aleksandra</forename><surname>Zwolinska</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vanessa</forename><surname>Depaepe</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tino</forename><surname>Hochepied</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">William</forename><forename type="middle">C</forename><surname>Skarnes</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jean-Christophe</forename><surname>Marine</surname></persName>
		</author>
		<idno type="DOI">10.1172/jci45784</idno>
		<idno type="PMID">21403399</idno>
		<idno type="PMCID">PMC3070608</idno>
		<ptr type="open-access" target="http://www.jci.org/articles/view/45784/files/pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Clinical Investigation</title>
		<title level="j" type="abbrev">J. Clin. Invest.</title>
		<idno type="ISSN">0021-9738</idno>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1329" to="1343" />
			<date type="published" when="2011-04-01" />
			<publisher>American Society for Clinical Investigation</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b32">
	<analytic>
		<title level="a" type="main">The IARC TP53 database: New online mutation analysis and recommendations to users</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Magali</forename><surname>Olivier</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ros</forename><surname>Eeles</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Monica</forename><surname>Hollstein</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mohammed</forename><forename type="middle">A</forename><surname>Khan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Curtis</forename><forename type="middle">C</forename><surname>Harris</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pierre</forename><surname>Hainaut</surname></persName>
		</author>
		<idno type="DOI">10.1002/humu.10081</idno>
		<idno type="PMID">12007217</idno>
		<idno type="ark">ark:/67375/WNG-W378TRN5-M</idno>
		<idno type="istexId">ED239FC2CB394C85B422172B0847626631ED7A57</idno>
	</analytic>
	<monogr>
		<title level="j">Human Mutation</title>
		<title level="j" type="abbrev">Hum. Mutat.</title>
		<idno type="ISSN">1059-7794</idno>
		<idno type="ISSNe">1098-1004</idno>
		<imprint>
			<biblScope unit="volume">19</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="607" to="614" />
			<date type="published" when="2002-05-03" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b33">
	<analytic>
		<title level="a" type="main">Bacterial cupredoxin azurin as an inducer of apoptosis and regression in human breast cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vasu</forename><surname>Punj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Suchita</forename><surname>Bhattacharyya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Djenann</forename><surname>Saint-Dic</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chenthamarakshan</forename><surname>Vasu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elizabeth</forename><forename type="middle">A</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jewell</forename><surname>Graves</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tohru</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andreas</forename><forename type="middle">I</forename><surname>Constantinou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Konstantin</forename><surname>Christov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bethany</forename><surname>White</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gang</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dibyen</forename><surname>Majumdar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ananda</forename><forename type="middle">M</forename><surname>Chakrabarty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tapas</forename><forename type="middle">K</forename><surname>Das Gupta</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.onc.1207376</idno>
		<idno type="PMID">14981543</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/1207376.pdf" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<title level="j" type="abbrev">Oncogene</title>
		<idno type="ISSN">0950-9232</idno>
		<idno type="ISSNe">1476-5594</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">13</biblScope>
			<biblScope unit="page" from="2367" to="2378" />
			<date type="published" when="2004-02-23" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b34">
	<analytic>
		<title level="a" type="main">Topors Functions as an E3 Ubiquitin Ligase with Specific E2 Enzymes and Ubiquitinates p53</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rajeev</forename><surname>Rajendra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Diptee</forename><surname>Malegaonkar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pooja</forename><surname>Pungaliya</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henderson</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zeshaan</forename><surname>Rasheed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">James</forename><surname>Brownell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Leroy</forename><forename type="middle">F</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Stuart</forename><surname>Lutzker</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ahamed</forename><surname>Saleem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eric</forename><forename type="middle">H</forename><surname>Rubin</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.c400300200</idno>
		<idno type="PMID">15247280</idno>
		<ptr type="open-access" target="http://www.jbc.org/content/279/35/36440.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Biological Chemistry</title>
		<title level="j" type="abbrev">J. Biol. Chem.</title>
		<idno type="ISSN">0021-9258</idno>
		<idno type="ISSNe">1083-351X</idno>
		<imprint>
			<biblScope unit="volume">279</biblScope>
			<biblScope unit="issue">35</biblScope>
			<biblScope unit="page" from="36440" to="36444" />
			<date type="published" when="2004-07-09" />
			<publisher>American Society for Biochemistry &amp; Molecular Biology (ASBMB)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b35">
	<analytic>
		<title level="a" type="main">ProtorP: a protein-protein interaction analysis server</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Reynolds</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Damerell</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><surname>Jones</surname></persName>
		</author>
		<idno type="DOI">10.1093/bioinformatics/btn584</idno>
		<idno type="PMID">19001476</idno>
		<idno type="ark">ark:/67375/HXZ-NHVVSL0W-4</idno>
		<idno type="istexId">075AADF573B268388DC060A0E2A205690A78D1B1</idno>
		<ptr type="open-access" target="https://academic.oup.com/bioinformatics/article-pdf/25/3/413/669608/btn584.pdf" />
	</analytic>
	<monogr>
		<title level="j">Bioinformatics</title>
		<title level="j" type="abbrev">Bioinformatics</title>
		<idno type="ISSN">1367-4803</idno>
		<idno type="ISSNe">1460-2059</idno>
		<imprint>
			<biblScope unit="volume">25</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="413" to="414" />
			<date type="published" when="2008-11-11" />
			<publisher>Oxford University Press (OUP)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b36">
	<analytic>
		<title level="a" type="main">The topoisomerase I- and p53-binding protein topors is differentially expressed in normal and malignant human tissues and may function as a tumor suppressor</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ahamed</forename><surname>Saleem</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jayeeta</forename><surname>Dutta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Diptee</forename><surname>Malegaonkar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Farheena</forename><surname>Rasheed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zeshaan</forename><surname>Rasheed</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rajeev</forename><surname>Rajendra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Henderson</forename><surname>Marshall</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Minje</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Honghua</forename><surname>Li</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Eric</forename><forename type="middle">H</forename><surname>Rubin</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.onc.1207700</idno>
		<idno type="PMID">15107820</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/1207700.pdf" />
	</analytic>
	<monogr>
		<title level="j">Oncogene</title>
		<title level="j" type="abbrev">Oncogene</title>
		<idno type="ISSN">0950-9232</idno>
		<idno type="ISSNe">1476-5594</idno>
		<imprint>
			<biblScope unit="volume">23</biblScope>
			<biblScope unit="issue">31</biblScope>
			<biblScope unit="page" from="5293" to="5300" />
			<date type="published" when="2004-04-26" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b37">
	<analytic>
		<title level="a" type="main">Identification of a minimal transforming domain of p53: negative dominance through abrogation of sequence-specific DNA binding.</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Shaulian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Zauberman</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Ginsberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Oren</surname></persName>
		</author>
		<idno type="DOI">10.1128/mcb.12.12.5581</idno>
		<idno type="PMID">1448088</idno>
		<idno type="PMCID">PMC360497</idno>
		<ptr type="open-access" target="https://mcb.asm.org/content/12/12/5581.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Molecular and Cellular Biology</title>
		<title level="j" type="abbrev">Mol. Cell. Biol.</title>
		<idno type="ISSN">0270-7306</idno>
		<idno type="ISSNe">1098-5549</idno>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="5581" to="5592" />
			<date type="published" when="1992-12" />
			<publisher>American Society for Microbiology</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b38">
	<analytic>
		<title level="a" type="main">Molecular basis of Pirh2-mediated p53 ubiquitylation</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yi</forename><surname>Sheng</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rob</forename><forename type="middle">C</forename><surname>Laister</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alexander</forename><surname>Lemak</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Bin</forename><surname>Wu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Elizabeth</forename><surname>Tai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Shili</forename><surname>Duan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jonathan</forename><surname>Lukin</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Maria</forename><surname>Sunnerhagen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sampath</forename><surname>Srisailam</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Murthy</forename><surname>Karra</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sam</forename><surname>Benchimol</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cheryl</forename><forename type="middle">H</forename><surname>Arrowsmith</surname></persName>
		</author>
		<idno type="DOI">10.1038/nsmb.1521</idno>
		<idno type="PMID">19043414</idno>
		<idno type="PMCID">PMC4075976</idno>
		<idno type="ark">ark:/67375/GT4-SFZXQLLK-S</idno>
		<idno type="istexId">940675E08E5393D9207A476C626FBF5F43AC1F5A</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc4075976?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Nature Structural &amp; Molecular Biology</title>
		<title level="j" type="abbrev">Nat Struct Mol Biol</title>
		<idno type="ISSN">1545-9993</idno>
		<idno type="ISSNe">1545-9985</idno>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1334" to="1342" />
			<date type="published" when="2008-11-30" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b39">
	<analytic>
		<title level="a" type="main">Probing the interaction between p53 and the bacterial protein azurin by single molecule force spectroscopy</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Monia</forename><surname>Taranta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Anna</forename><forename type="middle">Rita</forename><surname>Bizzarri</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Salvatore</forename><surname>Cannistraro</surname></persName>
		</author>
		<idno type="DOI">10.1002/jmr.869</idno>
		<idno type="PMID">18247358</idno>
		<idno type="ark">ark:/67375/WNG-56XW4CBJ-H</idno>
		<idno type="istexId">71E414FA1D795C862D4E53DA84D0681F7F687CC5</idno>
	</analytic>
	<monogr>
		<title level="j">Journal of Molecular Recognition</title>
		<title level="j" type="abbrev">J. Mol. Recognit.</title>
		<idno type="ISSN">0952-3499</idno>
		<idno type="ISSNe">1099-1352</idno>
		<imprint>
			<biblScope unit="volume">21</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="63" to="70" />
			<date type="published" when="2008-01" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b40">
	<analytic>
		<title level="a" type="main">Noncationic Peptides Obtained From Azurin Preferentially Enter Cancer Cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">B</forename><forename type="middle">N</forename><surname>Taylor</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">R</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Lekmine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Christov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Chakrabarty</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Bratescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Shilkaitis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Beattie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">K</forename><surname>Das Gupta</surname></persName>
		</author>
		<idno type="DOI">10.1158/0008-5472.can-08-2932</idno>
		<idno type="PMID">19147567</idno>
		<ptr type="open-access" target="http://cancerres.aacrjournals.org/content/69/2/537.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Cancer Research</title>
		<title level="j" type="abbrev">Cancer Research</title>
		<idno type="ISSN">0008-5472</idno>
		<idno type="ISSNe">1538-7445</idno>
		<imprint>
			<biblScope unit="volume">69</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="537" to="546" />
			<date type="published" when="2009-01-15" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b41">
	<analytic>
		<title level="a" type="main">Impact of low-frequency hotspot mutation R282Q on the structure of p53 DNA-binding domain as revealed by crystallography at 1.54 Å resolution</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Chao</forename><surname>Tu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yu-Hong</forename><surname>Tan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Gary</forename><surname>Shaw</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Zheng</forename><surname>Zhou</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Yawen</forename><surname>Bai</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ray</forename><surname>Luo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xinhua</forename><surname>Ji</surname></persName>
		</author>
		<idno type="DOI">10.1107/s0907444908003338</idno>
		<idno type="PMID">18453682</idno>
		<idno type="PMCID">PMC2631104</idno>
		<idno type="ark">ark:/67375/WNG-ZLC5ZSWW-X</idno>
		<idno type="istexId">CACFB19955B186C0F110BE06286992D221938048</idno>
		<ptr type="open-access" target="http://europepmc.org/articles/pmc2631104?pdf=render" />
	</analytic>
	<monogr>
		<title level="j">Acta Crystallographica Section D Biological Crystallography</title>
		<title level="j" type="abbrev">Acta Crystallogr D Biol Cryst</title>
		<idno type="ISSN">0907-4449</idno>
		<imprint>
			<biblScope unit="volume">64</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="471" to="477" />
			<date type="published" when="2008-04-19" />
			<publisher>International Union of Crystallography (IUCr)</publisher>
		</imprint>
	</monogr>
	<note>Pt 5</note>
</biblStruct>

<biblStruct xml:id="b42">
	<analytic>
		<title level="a" type="main">COP1 is a tumour suppressor that causes degradation of ETS transcription factors</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Alberto</forename><forename type="middle">C</forename><surname>Vitari</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kevin</forename><forename type="middle">G</forename><surname>Leong</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Kim</forename><surname>Newton</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Cindy</forename><surname>Yee</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Karen</forename><surname>O’rourke</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jinfeng</forename><surname>Liu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lilian</forename><surname>Phu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Rajesh</forename><surname>Vij</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ronald</forename><surname>Ferrando</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Suzana</forename><forename type="middle">S</forename><surname>Couto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Sankar</forename><surname>Mohan</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ajay</forename><surname>Pandita</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Jo-Anne</forename><surname>Hongo</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">David</forename><surname>Arnott</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ingrid</forename><forename type="middle">E</forename><surname>Wertz</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Wei-Qiang</forename><surname>Gao</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Dorothy</forename><forename type="middle">M</forename><surname>French</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vishva</forename><forename type="middle">M</forename><surname>Dixit</surname></persName>
		</author>
		<idno type="DOI">10.1038/nature10005</idno>
		<idno type="PMID">21572435</idno>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<title level="j" type="abbrev">Nature</title>
		<idno type="ISSN">0028-0836</idno>
		<idno type="ISSNe">1476-4687</idno>
		<imprint>
			<biblScope unit="volume">474</biblScope>
			<biblScope unit="issue">7351</biblScope>
			<biblScope unit="page" from="403" to="406" />
			<date type="published" when="2011-05-15" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b43">
	<analytic>
		<title level="a" type="main">Interplay between MDM2, MDMX, Pirh2 and COP1: the negative regulators of p53</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Lan</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Guifen</forename><surname>He</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Pingzhao</forename><surname>Zhang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Xiang</forename><surname>Wang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Mei</forename><surname>Jiang</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Long</forename><surname>Yu</surname></persName>
		</author>
		<idno type="DOI">10.1007/s11033-010-0099-x</idno>
		<idno type="PMID">20333547</idno>
		<idno type="ark">ark:/67375/VQC-R31XSDFB-9</idno>
		<idno type="istexId">29A10CB6779606267BF3CAA28564020D924DD918</idno>
	</analytic>
	<monogr>
		<title level="j">Molecular Biology Reports</title>
		<title level="j" type="abbrev">Mol Biol Rep</title>
		<idno type="ISSN">0301-4851</idno>
		<idno type="ISSNe">1573-4978</idno>
		<imprint>
			<biblScope unit="volume">38</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="229" to="236" />
			<date type="published" when="2010-03-24" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b44">
	<analytic>
		<title level="a" type="main">A first-in-class, first-in-human, phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with advanced solid tumours</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">A</forename><surname>Warso</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><forename type="middle">M</forename><surname>Richards</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Christov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Schaeffer</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Rae Bressler</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Majumdar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">S</forename><forename type="middle">A</forename><surname>Kennedy</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Beattie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">K</forename><surname>Das Gupta</surname></persName>
		</author>
		<idno type="DOI">10.1038/bjc.2013.74</idno>
		<idno type="PMID">23449360</idno>
		<idno type="PMCID">PMC3619084</idno>
		<ptr type="open-access" target="https://www.nature.com/articles/bjc201374.pdf" />
	</analytic>
	<monogr>
		<title level="j">British Journal of Cancer</title>
		<title level="j" type="abbrev">Br J Cancer</title>
		<idno type="ISSN">0007-0920</idno>
		<idno type="ISSNe">1532-1827</idno>
		<imprint>
			<biblScope unit="volume">108</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="1061" to="1070" />
			<date type="published" when="2013-02-28" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b45">
	<analytic>
		<title level="a" type="main">Assessment of sequence-based p53 gene analysis in human breast cancer: messenger RNA in comparison with genomic DNA targets</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><surname>Williams</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Norberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Ahmadian</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Ponten</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Bergh</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Inganas</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">J</forename><surname>Lundeberg</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Uhlen</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Chem</title>
		<imprint>
			<biblScope unit="volume">44</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="455" to="462" />
			<date type="published" when="1998" />
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b46">
	<analytic>
		<title level="a" type="main">Strategies for therapeutic targeting of the p53 pathway in cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><forename type="middle">G</forename><surname>Wiman</surname></persName>
		</author>
		<idno type="DOI">10.1038/sj.cdd.4401921</idno>
		<idno type="PMID">16557267</idno>
	</analytic>
	<monogr>
		<title level="j">Cell Death &amp; Differentiation</title>
		<title level="j" type="abbrev">Cell Death Differ</title>
		<idno type="ISSN">1350-9047</idno>
		<idno type="ISSNe">1476-5403</idno>
		<imprint>
			<biblScope unit="volume">13</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="921" to="926" />
			<date type="published" when="2006-03-24" />
			<publisher>Springer Nature</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b47">
	<analytic>
		<title level="a" type="main">Internalization of bacterial redox protein azurin in mammalian cells: entry domain and specificity</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tohru</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Arsenio</forename><forename type="middle">M</forename><surname>Fialho</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Vasu</forename><surname>Punj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Laura</forename><surname>Bratescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Tapas</forename><forename type="middle">K Das</forename><surname>Gupta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Ananda</forename><forename type="middle">M</forename><surname>Chakrabarty</surname></persName>
		</author>
		<idno type="DOI">10.1111/j.1462-5822.2005.00567.x</idno>
		<idno type="PMID">16153242</idno>
	</analytic>
	<monogr>
		<title level="j">Cellular Microbiology</title>
		<idno type="ISSN">1462-5814</idno>
		<imprint>
			<biblScope unit="volume">7</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="1418" to="1431" />
			<date type="published" when="2005-07-05" />
			<publisher>Wiley</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b48">
	<analytic>
		<title level="a" type="main">Bacterial redox protein azurin, tumor suppressor protein p53, and regression of cancer</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><surname>Goto</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">V</forename><surname>Punj</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">O</forename><surname>Zaborina</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>Chen</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Kimbara</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Majumdar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">E</forename><surname>Cunningham</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">K</forename><surname>Das Gupta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><forename type="middle">M</forename><surname>Chakrabarty</surname></persName>
		</author>
		<idno type="DOI">10.1073/pnas.222539699</idno>
		<idno type="PMID">12393814</idno>
		<idno type="PMCID">PMC137843</idno>
		<ptr type="open-access" target="http://www.pnas.org/content/99/22/14098.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Proceedings of the National Academy of Sciences</title>
		<title level="j" type="abbrev">Proceedings of the National Academy of Sciences</title>
		<idno type="ISSN">0027-8424</idno>
		<idno type="ISSNe">1091-6490</idno>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">22</biblScope>
			<biblScope unit="page" from="14098" to="14103" />
			<date type="published" when="2002-10-22" />
			<publisher>Proceedings of the National Academy of Sciences</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b49">
	<analytic>
		<title level="a" type="main">A peptide fragment of azurin induces a p53-mediated cell cycle arrest in human breast cancer cells</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><surname>Yamada</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">R</forename><forename type="middle">R</forename><surname>Mehta</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">F</forename><surname>Lekmine</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">K</forename><surname>Christov</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">M</forename><forename type="middle">L</forename><surname>King</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">D</forename><surname>Majumdar</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Shilkaitis</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">A</forename><surname>Green</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">L</forename><surname>Bratescu</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">C</forename><forename type="middle">W</forename><surname>Beattie</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">T</forename><forename type="middle">K</forename><surname>Das Gupta</surname></persName>
		</author>
		<idno type="DOI">10.1158/1535-7163.mct-09-0444</idno>
		<idno type="PMID">19808975</idno>
		<ptr type="open-access" target="http://mct.aacrjournals.org/content/8/10/2947.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Molecular Cancer Therapeutics</title>
		<title level="j" type="abbrev">Molecular Cancer Therapeutics</title>
		<idno type="ISSN">1535-7163</idno>
		<idno type="ISSNe">1538-8514</idno>
		<imprint>
			<biblScope unit="volume">8</biblScope>
			<biblScope unit="issue">10</biblScope>
			<biblScope unit="page" from="2947" to="2958" />
			<date type="published" when="2009-10-01" />
			<publisher>American Association for Cancer Research (AACR)</publisher>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b50">
	<analytic>
		<title level="a" type="main">Mutational Analysis of the p53 Core Domain L1 Loop</title>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Andrew</forename><surname>Zupnick</surname></persName>
		</author>
		<author>
			<persName xmlns="http://www.tei-c.org/ns/1.0"><forename type="first">Carol</forename><surname>Prives</surname></persName>
		</author>
		<idno type="DOI">10.1074/jbc.m603387200</idno>
		<idno type="PMID">16687402</idno>
		<ptr type="open-access" target="http://www.jbc.org/content/281/29/20464.full.pdf" />
	</analytic>
	<monogr>
		<title level="j">Journal of Biological Chemistry</title>
		<title level="j" type="abbrev">J. Biol. Chem.</title>
		<idno type="ISSN">0021-9258</idno>
		<idno type="ISSNe">1083-351X</idno>
		<imprint>
			<biblScope unit="volume">281</biblScope>
			<biblScope unit="issue">29</biblScope>
			<biblScope unit="page" from="20464" to="20473" />
			<date type="published" when="2006-05-10" />
			<publisher>American Society for Biochemistry &amp; Molecular Biology (ASBMB)</publisher>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
